Director/PDMR Shareholding

Summary by AI ^BETAClose X

GSK plc announced that Tony Wood, Chief Scientific Officer, received an initial notification regarding a transaction on February 18, 2026. Following the vesting of 25% of an award made in February 2021, Mr. Wood will receive a cash payment of £204,048.58, less applicable tax withholding, in respect of 8,996.851 notional ordinary shares, with each share valued at £22.68.

Disclaimer*

GSK PLC

19 February 2026

GSK plc (the 'Company')
Transaction notification

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Tony Wood
b)	Position/status	Chief Scientific Officer
c)	Initial notification/ amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	Ordinary shares of 31 ¼ pence each ('Ordinary Shares') ISIN: GB00BN7SWP63
b)	Nature of the transaction	Following the vesting on 18 February 2026 of 25% of an award made on 18 February 2021 under the GlaxoSmithKline Deferred Investment Award Programme, Tony Wood will receive a cash payment of £204,048.58 less applicable tax withholding in respect of 8,996.851 notional Ordinary Shares.
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			£22.68	8,996.851

d)	Aggregated information	N/A (single transaction)
	Aggregated volume Price
e)	Date of the transaction	2026-02-18
f)	Place of the transaction	N/A

About GSK

GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at www.gsk.com.

Registered in England & Wales:

No. 3888792

Registered Office:

79 New Oxford Street

London

WC1A 1DG

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END